Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Genetic Disease Phase II/ Phase III
Spain 
Details:
Treatment with leriglitazone demonstrated PPARg engagement in all patients within the target range required for efficacy as assessed by a biomarker (adiponectin).
Lead Product(s): Leriglitazone
Therapeutic Area: Genetic Disease Product Name: MIN-102
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.
Lead Product(s): Leriglitazone
Therapeutic Area: Genetic Disease Product Name: MIN-102
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 30, 2020
Details:
Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Lead Product(s): Leriglitazone
Therapeutic Area: Genetic Disease Product Name: MIN-102
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sperogenix Therapeutics
Deal Size: $78.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 23, 2020
